Atriva Therapeutics GmbH, with additional sites in Tübingen and Frankfurt am Main, Germany, is pursuing a novel approach to combating known and unknown viral respiratory infectious diseases, such as COVID-19 and influenza, using host cell proteins rather than the virus for therapy. Atriva’s lead product, zapnometinib (ATR-002), is a first-in-class host-targeted agent that inhibits viral replication and favorably affects the body’s immune response to RNA viruses. In September 2022, Atriva had published promising topline results from the proof of concept (POC)/phase 2a RESPIRE (zapnometinib) trial in patients with COVID-19.

